Trump Orders Faster Access to Psychedelic Treatments

President Trump signed an executive order directing federal agencies to accelerate access to psychedelic-based treatments, a move aligned with Health Secretary Robert F. Kennedy Jr.'s public advocacy for substances such as ibogaine as alternatives to conventional therapies for depression and other mental health conditions. The order signals a formal shift in federal posture toward a class of compounds that have remained largely restricted under existing drug scheduling law. Ibogaine, a psychoactive alkaloid derived from the iboga plant, has drawn clinical interest for treatment-resistant depression and opioid dependence but faces significant regulatory hurdles under Schedule I classification. The executive order's practical effect depends on how agencies, likely including the FDA and DEA, interpret and implement the directive, particularly whether it accelerates clinical trial pathways, expedites scheduling reviews, or enables broader compassionate-use access. Researchers and investors in the psychedelic therapeutics sector will be watching for follow-on regulatory guidance that translates the order's intent into enforceable policy change.